Lipocine (NASDAQ:LPCN) Lifted to Buy at StockNews.com

StockNews.com upgraded shares of Lipocine (NASDAQ:LPCN) from a hold rating to a buy rating in a research report released on Friday morning.

Lipocine Stock Up 1.5 %

LPCN opened at $4.84 on Friday. The company has a market cap of $25.88 million, a price-to-earnings ratio of -2.83 and a beta of 1.21. Lipocine has a 52-week low of $2.31 and a 52-week high of $11.79. The firm’s fifty day simple moving average is $4.58 and its two-hundred day simple moving average is $5.55.

Lipocine (NASDAQ:LPCN) last posted its quarterly earnings data on Thursday, August 8th. The specialty pharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter. The business had revenue of $0.09 million for the quarter. On average, research analysts forecast that Lipocine will post -0.92 EPS for the current year.

Institutional Investors Weigh In On Lipocine

An institutional investor recently bought a new position in Lipocine stock. Dimensional Fund Advisors LP acquired a new position in shares of Lipocine Inc. (NASDAQ:LPCN) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned about 0.22% of Lipocine at the end of the most recent quarter. 9.11% of the stock is currently owned by hedge funds and other institutional investors.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.